560 related articles for article (PubMed ID: 11477347)
1. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
Mycophenolate Mofetil Acute Renal Rejection Study Group
Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group.
Miller J; Mendez R; Pirsch JD; Jensik SC
Transplantation; 2000 Mar; 69(5):875-80. PubMed ID: 10755543
[TBL] [Abstract][Full Text] [Related]
8. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence.
Pham PT; Pham PC
Nephrol Dial Transplant; 2012 Jul; 27(7):2965-71. PubMed ID: 22207327
[TBL] [Abstract][Full Text] [Related]
9. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
Ulsh PJ; Yang HC; Holman MJ; Ahsan N
J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
Sollinger HW
Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients.
Silva HT; Yang HC; Meier-Kriesche HU; Croy R; Holman J; Fitzsimmons WE; First MR
Transplantation; 2014 Mar; 97(6):636-41. PubMed ID: 24521771
[TBL] [Abstract][Full Text] [Related]
12. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
[TBL] [Abstract][Full Text] [Related]
13. Outcome in cadaveric renal transplant recipients treated with cyclosporine A and mycophenolate mofetil versus cyclosporine A and azathioprine.
Lee CM; Markezich AJ; Scandling JD; Dafoe DC; Alfrey EJ
J Surg Res; 1998 May; 76(2):131-6. PubMed ID: 9698512
[TBL] [Abstract][Full Text] [Related]
14. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group.
Forsythe J
Transplant Proc; 1999 Nov; 31(7A):69S-71S. PubMed ID: 10576049
[No Abstract] [Full Text] [Related]
16. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
Włodarczyk Z; Wałaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradsky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Nagy KK; Hickey D
Ann Transplant; 2002; 7(3):28-31. PubMed ID: 12465429
[TBL] [Abstract][Full Text] [Related]
17. FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group.
Mendez R
Transplant Proc; 1998 Jun; 30(4):1287-9. PubMed ID: 9636522
[TBL] [Abstract][Full Text] [Related]
18. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
Guethoff S; Meiser BM; Groetzner J; Eifert S; Grinninger C; Ueberfuhr P; Reichart B; Hagl C; Kaczmarek I
Transplantation; 2013 Feb; 95(4):629-34. PubMed ID: 23423270
[TBL] [Abstract][Full Text] [Related]
19. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
20. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil.
Kimball JA; Pescovitz MD; Book BK; Norman DJ
Transplantation; 1995 Dec; 60(12):1379-83. PubMed ID: 8545860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
